FDA Clears IND for EOM613 Trial in Cancer Cachexia Patients
FDA clears IND for EOM613 trial in cancer cachexia patients. A 20-patient Phase 2a study tests whether this immune...
Jon Napitupulu
Zenas BioPharma Submits BLA for Obexelimab in IgG4-Related Disease
Zenas BioPharma submits BLA for obexelimab in IgG4-Related Disease, showing 56% flare reduction over 52 weeks with p=0.0005 across...
Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy
Senti Bio advances SENTI-202 pivotal trial with Donor X selection strategy, achieving 50% complete remission in heavily pretreated R/R...
Lifestyle Program Improves Brain Health in Cognitive Decline
Interim data from the PREVENTION clinical study report improvements in cerebral blood flow and insulin response among people with...
Inhibikase Enrolls First Patient in Phase 3 PAH Study
IMPROVE-PAH is a two-part adaptive Phase 3 program testing IKT-001, an oral prodrug of imatinib, in up to 180...
Incyclix Bio’s Hope: A Surging $5M for Cancer Trial
Incyclix Bio secured an additional $5 million extension to its Series B from Hatteras Venture Partners to advance INX-315,...
COACH trial: hGH accelerates CNP benefits in achondroplasia
At Week 52 in the Phase 2 COACH trial, once-weekly TransCon CNP plus once-weekly TransCon hGH delivered a mean...
Radiopharm Advances to Cohort 3 in Phase 1 Clinical Trial
Radiopharm Theranostics’ Phase 1 HEAT trial cleared its second safety gate, with the independent monitoring committee recommending dose escalation...
Incyclix Bio’s Promising Cancer Trial Gets New $5M Fund
Incyclix Bio secured an additional $5 million for its Series B to extend development of INX-315, a selective CDK2...
Pioneering gammaCore nVNS Study for PTSD Enrolls First Patient
electroCore’s gammaCore non-invasive vagus nerve stimulation device has entered PTSD clinical testing with the first eight of a planned...